In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

The 5th iPSC Drug Development Summit serves as a pivotal platform for uniting iPSC-based drug developers across the value ...

At ASCO 2025, Servier presented data in the IDH-mutated cancer space.

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Meanwhile, the MHRA has also warned all people seeking treatment with the so-called "skinny jabs" to beware of counterfeit ...

Europe follows a similar pattern, with data from the EU Clinical Trials Information System (CTIS) estimating that less than 0 ...